Drug Profile
GRC 3015
Latest Information Update: 13 Feb 2008
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 24 Sep 2004 No development reported - Preclinical for Asthma in India (unspecified route)
- 24 Sep 2004 No development reported - Preclinical for Chronic obstructive pulmonary disease in India (unspecified route)
- 12 Apr 2002 Preclinical trials in Chronic obstructive pulmonary disease in India (unspecified route)